Appointment of controversial FDA official rocking agency like “an atom bomb,” scientists there say

The recent appointment of Dr. Tracy Beth Høeg as acting director of the FDA’s Center for Drug Evaluation and Research has sparked concern among senior FDA officials. Høeg’s controversial stance as a vaccine skeptic and lack of experience in drug review and clinical trials have raised alarm bells within the agency. Many top-level officials are reportedly considering resigning in response to her appointment, viewing it as a significant blow to the FDA’s reputation as a trusted regulator of the nation’s drug supply.

Høeg’s background as a sports medicine physician and epidemiologist has been overshadowed by her advocacy for stricter restrictions on COVID vaccines, citing rare side effects like myocarditis. Her involvement in advising Commissioner Marty Makary on vaccine policy has drawn criticism, particularly after a memo claiming children had died from the COVID vaccine was released without supporting data.

In her new role, Høeg will oversee the evaluation of both over-the-counter and prescription drugs, as well as the approval of new pharmaceutical products. However, there are concerns that her appointment may lead to the politicization of the FDA’s drug evaluation process, potentially driving pharmaceutical companies to seek regulatory approval overseas.

During a recent CDC advisory panel meeting, Høeg questioned the childhood vaccination schedule in the U.S., suggesting that it may be excessive compared to other developed nations. Her views on vaccine recommendations have drawn scrutiny from medical experts, with the American Academy of Pediatrics defending the existing vaccination guidelines as evidence-based and consistent with international standards.

Despite the controversy surrounding her appointment, FDA Commissioner Marty Makary has expressed confidence in Høeg’s ability to modernize the drug regulator’s office and uphold scientific rigor in decision-making. However, concerns about declining trust in the healthcare system, vaccine mandates, and political polarization remain prominent issues that Høeg will need to address in her new role.

Høeg’s appointment follows a series of leadership changes within the FDA’s drug office, including the resignation of George Tidmarsh and the abrupt departure of Richard Pazdur, a veteran FDA scientist. Pazdur’s resignation reportedly stemmed from conflicts with Makary over the direction of the office, highlighting the internal challenges facing the agency’s leadership.

In conclusion, Dr. Tracy Beth Høeg’s appointment as acting director of the FDA’s Center for Drug Evaluation and Research has sparked controversy and raised concerns among FDA officials. Her background as a vaccine skeptic and lack of experience in drug evaluation have led to fears of politicization and potential harm to the agency’s reputation. The coming months will be crucial in determining how Høeg navigates these challenges and earns the trust of stakeholders in the pharmaceutical industry and the public.